Success Metrics

Active Trials

7(70%)

Phase Distribution

Ph phase_1

10%

Ph not_applicable

90%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

1(10.0%)

N/ANon-phased studies

9(90.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(10)

Detailed Status

Recruiting7

Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 11 (10.0%)

N/A9 (90.0%)

Trials by Status

not_yet_recruiting330%

recruiting770%

Recent Activity

7 active trials

Showing 5 of 10

recruitingnot_applicable

JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies

NCT07065279

recruitingnot_applicable

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

NCT06689917

recruitingnot_applicable

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

NCT06940960

recruitingnot_applicable

JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders

NCT06797024

recruitingnot_applicable

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

NCT06890065

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT07065279Not Applicable

JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies

Recruiting

NCT06689917Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

Recruiting

NCT06940960Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

Recruiting

NCT06797024Not Applicable

JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders

Recruiting

NCT06890065Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

Recruiting

NCT06902025Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia

Not Yet Recruiting

NCT06887985Not Applicable

JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)

Not Yet Recruiting

NCT06879470Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma

Not Yet Recruiting

NCT06678282Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

Recruiting

NCT06675422Phase 1

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)

Recruiting

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10